Abstract
Purpose
Dopamine agonists (DAs) are recommended as first-line treatment for patients with hyperprolactinemia. Generally, it is accepted that patients with hyperprolactinemia do not need lifelong medication, but the optimal timing for DA withdrawal has not been determined. The aim of this systematic review and meta-analysis is to assess the impact of DA withdrawal on the clinical outcomes of patients with hyperprolactinemia, and to explore possible factors affecting successful DA withdrawal.
Methods
The databases of PubMed, Cochrane and EMBASE were searched up to May 2016.
Results
The proportion of patients with persisting normoprolactinemia after DA withdrawal reached 36.6% in a random effects model (95% CI, 29.4–44.2%; I-squared: 82.5%). Data of stratified analysis showed that the success rate of drug withdrawal was high in patients using cabergoline (CAB) as the only treatment (41.2%; 95% CI 32.3–50.4%) and those using CAB over 24 months (48.7%; 95% CI 38.9–58.5%), especially in patients with idiopathic hyperprolactinemia (73.2%; 95% CI 55.6–87.7%). In addition, patients who received a low maintenance dose of CAB, and had a significant reduction in tumor size (over 50%) before withdrawal, were more likely to achieve success (51.5 and 49.4%, respectively).
Conclusion
The success rate of DA withdrawal has increased in recent years. Further, the success rate of CAB withdrawal was higher than that of bromocriptine, especially in patients with a duration of treatment longer than 24 months. Conclusively, the probability of success was higher in patients who received low-dose CAB maintenance treatment and those who achieved a significant reduction in tumor size before withdrawal.
Similar content being viewed by others
References
S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, J.A. Wass, Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(2), 273–288 (2011). https://doi.org/10.1210/jc.2010-1692
A. Colao, A. Di Sarno, E. Guerra, M. De Leo, A. Mentone, G. Lombardi, Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat. Clin. Pract. Endocrinol. Metab. 2(4), 200–210 (2006). https://doi.org/10.1038/ncpendmet0160
Z.B. Wu, C.J. Yu, Z.P. Su, Q.C. Zhuge, J.S. Wu, W.M. Zheng, Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J. Neurosurg. 104(1), 54–61 (2006). https://doi.org/10.3171/jns.2006.104.1.54
A. Colao, A. di Sarno, R. Pivonello, C. di Somma, G. Lombardi, Dopamine receptor agonists for treating prolactinomas. Expert Opin. Investig. Drugs 11(6), 787–800 (2002). https://doi.org/10.1517/13543784.11.6.787
M.P. Gillam, M.E. Molitch, G. Lombardi, A. Colao, Advances in the treatment of prolactinomas. Endocr. Rev. 27(5), 485–534 (2006). https://doi.org/10.1210/er.2005-9998
J.J. Orrego, W.F. Chandler, A.L. Barkan, Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine. Pituitary 3(3), 189–192 (2000)
M.E. Molitch, Medical treatment of prolactinomas. Endocrinol. Metab. Clin. N. Am. 28(1), 143–169 (1999)
M.O. Thorner, R.L. Perryman, A.D. Rogol, B.P. Conway, R.M. Macleod, I.S. Login, J.L. Morris, Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J. Clin. Endocrinol. Metab. 53(3), 480–483 (1981). https://doi.org/10.1210/jcem-53-3-480
F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert, M.D. Bronstein, T. Brue, P. Cappabianca, A. Colao, R. Fahlbusch, H. Fideleff, M. Hadani, P. Kelly, D. Kleinberg, E. Laws, J. Marek, M. Scanlon, L.G. Sobrinho, J.A. Wass, A. Giustina, Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65(2), 265–273 (2006). https://doi.org/10.1111/j.1365-2265.2006.02562.x
O.M. Dekkers, J. Lagro, P. Burman, J.O. Jorgensen, J.A. Romijn, A.M. Pereira, Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 95(1), 43–51 (2010). https://doi.org/10.1210/jc.2009-1238
P. Anagnostis, F. Adamidou, S.A. Polyzos, Z. Efstathiadou, E. Karathanassi, M. Kita, Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary 15(1), 25–29 (2012). https://doi.org/10.1007/s11102-011-0303-6
J. Kharlip, R. Salvatori, G. Yenokyan, G.S. Wand, Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J. Clin. Endocrinol. Metab. 94(7), 2428–2436 (2009). https://doi.org/10.1210/jc.2008-2103
A. Colao, A. Di Sarno, P. Cappabianca, C. Di Somma, R. Pivonello, G. Lombardi, Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N. Engl. J. Med. 349(21), 2023–2033 (2003). https://doi.org/10.1056/NEJMoa022657
J.P. Higgins, S.G. Thompson, J.J. Deeks, D.G. Altman, Measuring inconsistency in meta-analyses. BMJ 327(7414), 557–560 (2003). https://doi.org/10.1136/bmj.327.7414.557
R. Kwancharoen, R.S. Auriemma, G. Yenokyan, G.S. Wand, A. Colao, R. Salvatori, Second attempt to withdraw cabergoline in prolactinomas: a pilot study. Pituitary 17(5), 451–456 (2014). https://doi.org/10.1007/s11102-013-0525-x
L. Vilar, J.L. Albuquerque, P.S. Gadelha, F. Rangel Filho, A.M. Siqueira, M.M. da Fonseca, K.F. Viana, B.S. Gomes, R. Lyra, Second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: is it worthwhile? Front. Endocrinol. 6, 11 (2015). https://doi.org/10.3389/fendo.2015.00011
G. Faglia, A. Conti, M. Muratori, E. Togni, P. Travaglini, A. Zanotti, F. Mailland, Dihydroergocriptine in management of microprolactinomas. J. Clin. Endocrinol. Metab. 65(4), 779–784 (1987). https://doi.org/10.1210/jcem-65-4-779
A. Liuzzi, D. Dallabonzana, G. Oppizzi, G.G. Verde, R. Cozzi, P. Chiodini, G. Luccarelli, Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N. Engl. J. Med. 313(11), 656–659 (1985). https://doi.org/10.1056/nejm198509123131103
A. Di Sarno, M.L. Landi, P. Marzullo, C. Di Somma, R. Pivonello, G. Cerbone, G. Lombardi, A. Colao, The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin. Endocrinol. 53(1), 53–60 (2000)
W. Winkelmann, B. Allolio, U. Deuss, D. Heesen, D. Kaulen, in Persisting Normoprolactinemia After Withdrawal of Bromocriptine Long-term Therapy in Patients with Prolactinomas, (ed.), by R.M. Macleod, M.O. Thorner, U. Scapagnini. Basic and Clinical Correlates (Liviana Press, Padova, 1985), pp. 817–822
M. Giusti, E. Porcella, A. Carraro, M. Cuttica, S. Valenti, G. Giordano, A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients. J. Endocrinol. Investig. 17(1), 51–57 (1994). https://doi.org/10.1007/bf03344963
V.Q. Passos, J.J. Souza, N.R. Musolino, M.D. Bronstein, Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J. Clin. Endocrinol. Metab. 87(8), 3578–3582 (2002). https://doi.org/10.1210/jcem.87.8.8722
A. Zarate, E.S. Canales, C. Cano, C.J. Pilonieta, Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol. 104(2), 139–142 (1983)
S. Cannavo, L. Curto, S. Squadrito, B. Almoto, A. Vieni, F. Trimarchi, Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J. Endocrinol. Investig. 22(5), 354–359 (1999). https://doi.org/10.1007/bf03343573
M. Muratori, M. Arosio, G. Gambino, C. Romano, O. Biella, G. Faglia, Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J. Endocrinol. Investig. 20(9), 537–546 (1997). https://doi.org/10.1007/bf03348016
M.S. Huda, N.B. Athauda, M.M. Teh, P.V. Carroll, J.K. Powrie, Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin. Endocrinol. 72(4), 507–511 (2010). https://doi.org/10.1111/j.1365-2265.2009.03657.x
T.M. Barber, J. Kenkre, C. Garnett, R.V. Scott, J.V. Byrne, J.A. Wass, Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma. Clin. Endocrinol. 75(6), 819–824 (2011). https://doi.org/10.1111/j.1365-2265.2011.04136.x
E.E. Buyukbayrak, A.Y. Karageyim Karsidag, B. Kars, O. Balcik, M. Pirimoglu, O. Unal, C. Turan, Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia. Arch. Gynecol. Obstet. 282(5), 561–566 (2010). https://doi.org/10.1007/s00404-010-1562-6
P. Moriondo, P. Travaglini, M. Nissim, A. Conti, G. Faglia, Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J. Clin. Endocrinol. Metab. 60(4), 764–772 (1985). https://doi.org/10.1210/jcem-60-4-764
M. Biswas, J. Smith, D. Jadon, P. McEwan, D.A. Rees, L.M. Evans, M.F. Scanlon, J.S. Davies, Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin. Endocrinol. 63(1), 26–31 (2005). https://doi.org/10.1111/j.1365-2265.2005.02293.x
J.W. van‘t Verlaat, R.J. Croughs, Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin. Endocrinol. 34(3), 175–178 (1991)
C. Ferrari, A. Paracchi, A.M. Mattei, S. de Vincentiis, A. D’Alberton, P. Crosignani, Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta. Endocrinol. 126(6), 489–494 (1992)
K.Y. Ho, G.A. Smythe, P.J. Compton, L. Lazarus, Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia. Aust. N. Z. J. Med. 15(2), 213–219 (1985)
A.M. Mattei, C. Ferrari, G. Ragni, R. Benco, M.C. Picciotti, P. Rampini, R. Caldara, P.G. Crosignani, Serum prolactin and ovarian function after discontinuation of drug treatment for hyperprolactinaemia: a study with bromocriptine and metergoline. Br. J. Obstet. Gynaecol. 91(3), 244–250 (1984)
M. Martin de Santa-Olalla y Llanes, V.M. Andia Melero, A. Jara Albarran, [Long-term evolution and outcomes of microprolactinoma with medical treatment]. Endocrinol. Nutr. 60(9), 489–494 (2013). https://doi.org/10.1016/j.endonu.2013.03.007
S.C. Dogansen, O.S. Selcukbiricik, S. Tanrikulu, S. Yarman, Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when? Pituitary 19(3), 303–310 (2016). https://doi.org/10.1007/s11102-016-0708-3
E. Sala, P. Bellaviti Buttoni, E. Malchiodi, E. Verrua, G. Carosi, E. Profka, G. Rodari, M. Filopanti, E. Ferrante, A. Spada, G. Mantovani, Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. J. Endocr. Investig. (2016). https://doi.org/10.1007/s40618-016-0483-z
A. Colao, A. Di Sarno, E. Guerra, R. Pivonello, P. Cappabianca, F. Caranci, A. Elefante, L.M. Cavallo, F. Briganti, S. Cirillo, G. Lombardi, Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin. Endocrinol. 67(3), 426–433 (2007). https://doi.org/10.1111/j.1365-2265.2007.02905.x
M. Coculescu, N. Simionescu, M. Oprescu, D. Alessandrescu, Bromocriptine treatment of pituitary adenomas. Evaluation of withdrawal effect. Endocrinologie 21(3), 157–168 (1983)
T. Eversmann, R. Fahlbusch, H.K. Rjosk, K. von Werder, Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas. Acta. Endocrinol. 92(3), 413–427 (1979)
W.S. Maxson, M. Dudzinski, S.H. Handwerger, C.B. Hammond, Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Fertil. Steril. 41(2), 218–223 (1984)
L.G. Sobrinho, M.C. Nunes, C. Calhaz-Jorge, J.C. Mauricio, M.A. Santos, Effect of treatment with bromocriptine on the size and activity of prolactin producing pituitary tumours. Acta. Endocrinol. 96(1), 24–29 (1981)
J. Hu, X. Zheng, W. Zhang, H. Yang, Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary 18(5), 745–751 (2015). https://doi.org/10.1007/s11102-014-0617-2
M.E. Molitch, Pituitary gland: can prolactinomas be cured medically? Nat. Rev. Endocrinol. 6(4), 186–188 (2010). https://doi.org/10.1038/nrendo.2009.278
Acknowledgements
We thank Ms. Erin M. Botticelli of Massachusetts General Hospital for her careful reading and editing of the manuscript.
Funding
This work was supported by Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (Grant No. 20161407), and the National Natural Science Foundation of China (Grant No. 81471392, 81271523).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Additional information
Miao Yun Xia and Xiao Hui Lou contributed equally to this work.
Rights and permissions
About this article
Cite this article
Xia, M.Y., Lou, X.H., Lin, S.J. et al. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine 59, 50–61 (2018). https://doi.org/10.1007/s12020-017-1444-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-017-1444-9